Clinical Efficacy of Apalutamide Combined with DP Chemotherapy Regimen for Metastatic Castration-Resistant Prostate Cancer
Objective To investigate the clinical efficacy of apalutamide combined with docetaxel+prednisone(DP)chemotherapy regimen for metastatic castration-resistant prostate cancer.Methods Eighty-two patients with metastatic castration-resistant prostate cancer in the First Affiliated Hospital of Zhengzhou University from January 2020 to January 2022 were enrolled,and classified into two groups according to different treatment methods.Control group(42 cases)adopted DP chemotherapy regimen,while treatment group(40 cases)was given apalutamide combined with DP chemotherapy.Then the clinical outcomes,serum prostate-specific antigen and testosterone levels,adverse effects,and survival rate were compared between two groups.Results The overall response rate was 70.00％in treatment group,which was higher than 47.62％in control group(P＜0.05).After treatment,the levels of prostate specific antigen and testosterone in treatment group were lower than those in control group(P＜0.05).Only 2 patients in control group developed acute grade Ⅲ gastrointestinal toxicity(nausea and vomiting),and the rest adverse reactions were mild(degree Ⅰ-Ⅱ).In treatment group,gastrointestinal toxicity(nausea and vomiting)occurred in 16 cases(40.00％),leukopenia in 11 cases(27.50％),alopecia in 8 cases(20.00％),fatigue in 6 cases(15.00％),hepatotoxicity in 4 cases(10.00％),and granulocytopenia in 2 cases(5.00％).In control group,gastrointestinal toxicity(nausea and vomiting)occurred in 14 cases(33.33％),leukopenia in 4 cases(9.52％),alopecia in 9 cases(21.43％),fatigue in 5 cases(11.90％),hepatotoxicity in 2 cases(4.76％),and granulocytopenia in 1 case(2.38％).The total adverse reaction rate yielded no statistical difference between two groups(P＞0.05).The median prostate-specific antigen progression-free survival in the treatment and control groups was 8.4 months(95％CI:11.87-13.88)and 7.0 months(95％CI:10.57-12.72),respectively,and prostate-specific survival was longer than the control group(P＜0.05).Conclusion Application of apalutamide combined with DP chemotherapy regimen for metastatic castration-resistant prostate cancer can effectively improve the prostate specific antigen and testosterone levels without increasing adverse reactions,thus prolonging prostate specific antigen progression free survival.
apalutamidedocetaxelprednisonemetastatic castration-resistant prostate cancerprostate specific antigen
NETL
NSTL
万方数据
